Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Vasculitis
•
GCA
•
Large vessel vasculitis
What is your approach to patients with GCA who have difficulty with prednisone weaning (20mg) despite use of tocilizumab?
Is there benefit of addition of a DMARD such as methotrexate? Would you revisit diagnosis?
Related Questions
How would you approach management of nodular scleritis in the setting of suspected GCA?
Would you consider tocilizumab for treatment of GCA in patients with underlying CLL (not requiring therapy)?
Do you utilize temporal artery ultrasound in your practice?
Do you avoid tocilizumab in patients with prior bariatric surgery given the risk of GI perforation?
How do you approach the management of digital ischemia in a critically ill patient with infection, but no evidence of active rheumatologic disease?
How long do you continue PJP prophylaxis in a patient with GPA who is able to wean steroids and remains only on rituximab for maintenance therapy?
Do you extend the duration of maintenance therapy past 24 months for patients with ANCA glomerulonephritis who have multiple organ involvement?
How would you approach management of a patient with classic GCA symptoms, elevated ESR and improvement with steroids, but negative temporal artery biopsy and CTA imaging without evidence of vasculitis?
How do you approach the workup of clinically diagnosed cutaneous vasculitis in healthy young individuals without systemic symptoms?
How would you interpret the presence of both high titer anti-PR3 and anti-MPO antibodies in a pANCA positive patient with evidence of small vessel vasculitis?